Pro-2-PAM therapy for central and peripheral cholinesterases. - Wikidata - awgldk - TriplyDB

Pro-2-PAM therapy for central and peripheral cholinesterases.

Pro-2-PAM therapy for central and peripheral cholinesterases.

http://www.wikidata.org/entity/Q41240603

about

A conformational change in the peripheral anionic site of Torpedo californica acetylcholinesterase induced by a bis-imidazolium oxime Mechanism of interaction of novel uncharged, centrally active reactivators with OP-hAChE conjugates New structural scaffolds for centrally acting oxime reactivators of phosphylated cholinesterases.Refinement of structural leads for centrally acting oxime reactivators of phosphylated cholinesterases."All in the mind"? Brain-targeting chemical delivery system of 17β-estradiol (Estredox) produces significant uterotrophic side effect Mini review on blood-brain barrier penetration of pyridinium aldoximes.Post-exposure treatment with the oxime RS194B rapidly reverses early and advanced symptoms in macaques exposed to sarin vapor.Preclinical studies of noncharged oxime reactivators for organophosphate exposure.Post-exposure treatment with the oxime RS194B rapidly reactivates and reverses advanced symptoms of lethal inhaled paraoxon in macaques.The oxime pro-2-PAM provides minimal protection against the CNS effects of the nerve agents sarin, cyclosarin, and VX in guinea pigs.The biodistribution and pharmacokinetics of the oxime acetylcholinesterase reactivator RS194B in guinea pigs.New therapeutic approaches and novel alternatives for organophosphate toxicity.

P2860

Q27702043-15D16A77-CB68-4B41-9AFF-30FD51D80DA8 Q34414091-AEE0ED57-EA4C-442C-B6B4-3D804FA5E999 Q35010941-09CE1AC7-022E-4F07-8A14-D4748C76A8F9 Q35874368-1EDECF5A-6FB1-4F93-A146-0995BD873896 Q37417235-99F1DD62-2D80-41E1-8028-A2B89BDFAEA2 Q38257801-3707A6BA-2B40-46C6-B0CA-77F71E2E7714 Q38685670-A4CEB1C6-4E49-48D8-A4BB-7A3FB9FEA9A2 Q45874550-50117A97-B6E4-408E-A877-40BF316D6B7F Q46314151-EB4D70ED-DC9D-449D-8151-B0F61B4254B1 Q46897919-B3BFD03A-3BBC-472B-BD2B-79E4201615F4 Q46950790-53E771EB-7C65-4B4D-BA48-1363D5A43991 Q52610011-EEA48F35-FD61-4E2B-8A2C-D06B4C213336

P2860

Pro-2-PAM therapy for central and peripheral cholinesterases.

http://www.wikidata.org/entity/Q41240603

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Pro-2-PAM therapy for central and peripheral cholinesterases.

@en

type

label

Pro-2-PAM therapy for central and peripheral cholinesterases.

@en

prefLabel

Pro-2-PAM therapy for central and peripheral cholinesterases.

@en

P1433

Q41240603-16BF708E-E482-4825-A3B9-6280C1E129B0

P1476

Q41240603-F6E07F98-59E1-4913-9534-BB51606FC117

P2093

Q41240603-0722BAD1-3A0A-45EC-B3CB-ED13ACC661C3

Q41240603-24A7B250-29A4-4D2E-8A8B-AE54C29DBDCE

Q41240603-56AC6C22-85AE-4CCB-B49D-F71A0659B6AC

Q41240603-5C855132-2B2A-4AE2-8701-2039B6ED844A

Q41240603-624C78C9-A1E2-4435-872F-ED8181A9B674

Q41240603-6F8CE3C4-C4A4-4542-B576-522174B07062

Q41240603-8C120C9B-9A2F-443B-BD7D-F9055D327107

Q41240603-9904ACB5-F72D-4B2F-984E-E39F0A18A146

Q41240603-A0C70721-FE39-4E1E-843F-BAA4E81A47EC

Q41240603-B4F4E025-9F0D-48B3-BAB6-A970B8896619

P2860

Q41240603-08DAA4CA-A57E-4479-9FAB-4426BB9F5410

Q41240603-13C37C22-3D57-4FA3-99FF-D1889B857E7C

Q41240603-13D864FD-CEE9-4A17-8DF1-7450AFCCD695

Q41240603-188C1C06-53C0-4052-980F-A22E762F42D5

Q41240603-20A3B8FB-0E66-4625-B172-2D614F058B80

Q41240603-27612E9B-C1D4-4FFA-826E-1B2415AB4102

Q41240603-50B11BB9-AFE5-46FC-A572-A43B5D8F6812

Q41240603-5AE267A9-F089-40B0-B1D8-36A0FFB33A29

Q41240603-89D776E6-CE0D-425C-A162-172EF0DEAD24

Q41240603-8C0E69F1-FF67-48D9-B6DF-99E4CAC7776A

P304

Q41240603-195664C1-B476-401C-8F64-04550D87794B

P31

Q41240603-53615E17-FD7A-4F7F-B54D-8AD8651709F3

P356

Q41240603-9768CD06-EF58-4E92-B769-6A0E1D7979E7

P433

Q41240603-9599B15A-A6B7-4B4E-9D40-820047E20A2E

P478

Q41240603-91F1DE2E-8090-4056-8099-17BB19E79574

P50

Q41240603-71571FE8-F2F2-439E-8864-321E142A4D16

P577

Q41240603-2EE478F3-3C41-492A-A750-84234E216AC0

P5875

Q41240603-992736AD-BC51-4456-B991-97B1D1D6E89F

P698

Q41240603-44DF0E2F-15CB-46D7-B2FC-4B2E22389A86

P932

Q41240603-5C49D348-C630-4798-82C1-6CC1803C8271

P356

J.CBI.2010.02.015

P1433

Chemico-biological Interactions

P1476

Pro-2-PAM therapy for central and peripheral cholinesterases

@en

P2093

Amy J Campbell

http://www.w3.org/2001/XMLSchema#string

Edward D Clarkson

http://www.w3.org/2001/XMLSchema#string

Elizabeth Marek

http://www.w3.org/2001/XMLSchema#string

Farhat A Khan

http://www.w3.org/2001/XMLSchema#string

Haim Leader

http://www.w3.org/2001/XMLSchema#string

James C Demar

http://www.w3.org/2001/XMLSchema#string

Madhusoodana P Nambiar

http://www.w3.org/2001/XMLSchema#string

Marie A Medynets

http://www.w3.org/2001/XMLSchema#string

Richard K Gordon

http://www.w3.org/2001/XMLSchema#string

Roberta R Owens

http://www.w3.org/2001/XMLSchema#string

P2860

Status epilepticus: an overview of the clinical problem.

Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems.

The role of oximes in the treatment of nerve agent poisoning in civilian casualties.

Therapy for nerve agent poisoning.

Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction.

Red blood cell acetylcholinesterase and plasma butyrylcholinesterase status: important indicators for the treatment of patients poisoned by organophosphorus compounds.

Effects of atropine sulphate on seizure activity and brain damage produced by soman in guinea-pigs: ECoG correlates of neuropathology.

Improved delivery through biological membranes. 1. Synthesis and properties of 1-methyl-1,6-dihydropyridine-2-carbaldoxime, a pro-drug of N-methylpyridinium-2-carbaldoxime chloride.

Effects of sarin on the nervous system of subway workers seven years after the Tokyo subway sarin attack.

The combined effects of pyridostigmine and chronic stress on brain cortical and blood acetylcholinesterase, corticosterone, prolactin and alternation performance in rats.

P304

191-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CBI.2010.02.015

http://www.w3.org/2001/XMLSchema#string

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P50

Christine Herdman

P577

2010-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41434871

http://www.w3.org/2001/XMLSchema#string

P698

20156430

http://www.w3.org/2001/XMLSchema#string

P932

2889221

http://www.w3.org/2001/XMLSchema#string